



# Revvity Expands Access to Base Editing Technology With Aim to Accelerate Discovery to Cure

9/26/2023

- Launch of Pin-point™ base editing reagents improves access to new-generation editing technology
- Access to the Pin-point system now bridges discovery, preclinical and clinical with the same technology platform
- Reagent launch puts clinically relevant base editing in the hands of preclinical laboratories seeking to accelerate genomic insights and cell therapy research

WALTHAM, Mass.--(BUSINESS WIRE)-- **Revvity**, Inc., (NYSE: RVTY) today unveils its groundbreaking **Pin-point™ base editing** platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories. Base editing represents a pivotal advancement in CRISPR gene editing, providing the capability for complex and safe multi-gene editing, which can result in enhanced functional genomics insights for optimizing drug development, as well as streamlining cell line and cell therapy development and manufacturing. The Pin-point platform is one of the few established base editing technologies currently being employed in clinical settings, positioning it as both a discovery and therapeutic tool.

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

The initial reagents launch includes mRNAs for nCas9 and rat APOBEC, as well as three guide RNAs designed to knockout the TRAC, CD58 and PDCD1 loci. These reagents have undergone extensive validation and have demonstrated their performance in T-cells and induced pluripotent stem cells (iPSCs). Furthermore, Revvity offers

the flexibility of ordering custom guides for other targets through its **Dharmacon™ custom gRNA ordering tool for the Pin-point base editing platform**, supporting diverse research applications.

## Increasing Access to Accelerate Discovery to Cure

The introduction of Pin-point base editing reagents signifies a momentous stride toward democratizing access to base editing. Until now, base editing reagents were either custom-ordered by end-users or obtained by non-profit laboratories as individual components. However, with the newly launched reagents, scientists now have the ability to fully evaluate the Pin-point base editing platform in-house.

Alan Fletcher, senior vice president of life sciences at Revvity, emphasizes the importance of bridging the gap between discovery, diagnosis and cure: "In an era where the lines between precision and personalized medicine are increasingly blurred, translating genomic insights into clinically relevant actions is pivotal for us to expedite tomorrow's groundbreaking therapies and drive innovation from target identification to cure. Revvity is uniquely poised to drive these translational breakthroughs by offering accessible technologies like the Pin-point platform that seamlessly span the journey from discovery to therapy."

Furthering that aim, Revvity **announced** earlier this year it entered into a non-exclusive license agreement with AstraZeneca, granting access to its Pin-point base editing technology to help advance the biopharma company's work in cell therapy for the treatment of cancer and immune-mediated diseases.

## About Revvity

At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2022 revenue of more than \$3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our **Newsroom, LinkedIn, X, YouTube, Facebook** and **Instagram**.

## Investor Relations:

Steve Willoughby

(781) 663-5677

[steve.willoughby@revvity.com](mailto:steve.willoughby@revvity.com)

Media Relations:

Mary Karpa

(215) 896-4022

**[mary.karpa@revvity.com](mailto:mary.karpa@revvity.com)**

Source: Revvity